GlassScriptPhysician profile
Christina D Young
NPI 1467852095
$9,850.14
in general payments reported to CMS, 2019-2025
29 companies · $2,192 in 2025
The $2,192 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,593 · 2022: $2,087 · 2023: $1,677 · 2024: $2,302 · 2025: $2,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,919 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,919.40 |
| Education | $250.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,597.28 | 2021-2025 | |
| Janssen Biotech, INC. | $1,210.88 | 2021-2025 | Tremfya |
| Genzyme Corporation | $884.60 | 2021-2025 | |
| Incyte Corporation | $793.20 | 2021-2024 | Opzelura |
| Pfizer INC. | $775.98 | 2021-2025 | |
| Amgen INC. | $680.99 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $584.84 | 2023-2025 | |
| Lilly USA, LLC | $583.95 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $485.62 | 2021-2025 | Ilumya |
| Dermavant Sciences, INC. | $397.79 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $395.20 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $274.22 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $215.23 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $133.80 | 2021-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $124.84 | 2021-2025 | Cabtreo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $123.93 | 2023-2025 | Sotyktu |
| Organon LLC | $94.50 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $85.58 | 2021-2025 | |
| Almirall LLC | $60.92 | 2022-2024 | Klisyri |
| Dermira, INC. | $59.41 | 2021 | |
| Botanix Sb INC | $52.01 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.03 | 2023-2024 | Spevigo |
| Sanofi-Aventis U.S. LLC | $42.30 | 2021-2023 | |
| Arcutis Biotherapeutics, INC. | $41.19 | 2023 | |
| Conmed Corporation | $30.39 | 2025 | Visiclear |
| Verrica Pharmaceuticals INC. | $25.01 | 2023 | Ycanth |
| Journey Medical Corporation | $17.54 | 2022 | |
| Biofrontera INC. | $16.76 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Nabriva Therapeutics, Plc | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.